Supply Chain Archives
06/04/2025
Engineering for Impact: A Conversation with Mike Dybicz on the HV3 and Safepak Systems
When it comes to cell and gene therapy (CGT) logistics, innovation is about more than improving efficiency, it’s about safeguarding a patient’s only chance at treatment. We sat down with Mike Dybicz, Senior Vice President & Chief Product Development Officer, to discuss how Cryoport Systems is reshaping the future of CGT logistics with innovative products such as Cryoport Express® Cryogenic HV3 Shipping System and Safepak® System 1800, designed specifically to reduce risk, increase reliability, and ultimately improve patient outcomes.
06/01/2025
Honoring Survivors, Enabling the Future
Each year on the first Sunday in June, National Cancer Survivors Day serves as a powerful reminder that behind every innovation in medicine, every breakthrough treatment, and every clinical milestone, there are human stories of courage, resilience, and hope. At Cryoport Systems, we pause today not only to recognize the strength of cancer survivors but also to reflect on how our work supports the treatments that are changing survival outcomes.
05/29/2025
Starting Smart: How to Structure an Integrated Supply Chain in Early-Stage CGT Programs
For many academic labs, technology spinouts, and early-stage CGT companies, the temperature-controlled supply chain feels like something to figure out later. But when dealing with highly sensitive starting materials and therapies like CGTs, later can quickly become too late. Whether you’re preparing for first-in-human trials or just beginning to plan for scale, integrated thinking now can spare you time, cost, and complexity later.
05/20/2025
Why Animal Health Supply Chains Require Uncompromising Quality
Quality failures in animal health logistics do more than delay delivery, they put animal welfare at risk, threaten product efficacy, and erode public trust in veterinary medicine. Today’s biologics and vaccines are often made with temperature-sensitive proteins, viral vectors, or living cells, making the cold chain a essential operational function that directly impacts both clinical outcomes and commercial success.
04/16/2025
Delivering Over 5 Billion Doses of Biotherapeutics to Protect Animal Health Worldwide
In 2024, Cryoport Systems achieved a remarkable milestone: the delivery of over 5 billion doses of biotherapeutics, including cell-based therapies, antibody-based therapies, and vaccines to the global animal health industry. This achievement is the result of our unwavering commitment to ensuring the health and well-being of animals across the world, from livestock that sustain global food supply chains to the beloved companion animals that enrich our lives.
04/14/2025
Enabling the Outcome Through Enhancing Patient Accessibility
Cell and Gene Therapy (CGT) has emerged as one of the most transformative areas in modern medicine, shaping the future of healthcare and changing the face of next-generation therapeutic approaches. Yet, despite the continued scientific progress, a critical challenge persists in ensuring these therapies are accessible to the patients who need them most. This challenge was the focus of the keynote address at the Advanced Therapies Congress in London, delivered by Aruna Mor, Chief Commercial Officer at Cryoport Systems, where she spoke about to the state of patient access within the field of advanced therapeutics.
03/21/2025
Optimizing ATMP Cryopreservation: How IntegriCell™ Services in Belgium Ensure Cell Viability and Supply Chain Integrity
Cryopreservation is quickly becoming a critical yet often underestimated component of the Advanced Therapy Medicinal Product (ATMP) supply chain. The success of cell-based therapies depends on maintaining cell viability, stability, and consistency, yet variability in cryopreservation methods has compromised therapeutic outcomes.
03/12/2025
The Gateway to Europe: How Cryoport Systems’ Stevenage Supply Chain Hub Supports ATMP Development
For UK-based Advanced Therapy Medicinal Product (ATMP) developers, access to European clinical trial sites and commercial markets is a critical component of a successful growth strategy. Yet, navigating regulatory barriers, customs challenges, and supply chain complexities can create unnecessary delays, increase costs, and put the integrity of sensitive biologics at risk.
02/20/2025
